ideasIdea
A ten-dollar blood test for the five cancers that kill most people in poorer countries
Most cancer deaths are in low and middle income countries, where scans and endoscopies are scarce. A cheap methylation blood test tuned to liver, stomach, oesophageal, cervical and breast cancer could fill the gap.
Current MCEDs cost around $950 and target the US cancer mix. Propose a narrow-panel targeted-methylation assay on low-cost sequencing or PCR, optimised for cancers with high LMIC burden, validated in prospective LMIC cohorts, with a two-step protocol (positive leads to ultrasound or endoscopy).
Hypothesis
A five-cancer assay with marginal cost of $10 or less achieves at least 60% stage I-II sensitivity for liver, gastric and oesophageal cancer at 99% specificity, and is cost-effective at LMIC thresholds.
Rationale
Narrowing the target set and using PCR rather than deep sequencing sharply cuts cost; liver and gastric cancers shed methylated DNA relatively well.
What would test it
Case-control development, then a prospective 20,000-person cohort in a high-incidence region.
Maturity
speculative
Who has to act
philanthropy
Cost to try
Medium ($1M to $50M)
Years to first evidence
6
Bottlenecks it attacks
- Most lethal cancers are found late · Screening exists for only a few cancers. Pancreatic, ovarian, liver, oesophageal and most lung cancers are found when cure is unlikely.
- Most of the world has almost no cancer care · Seven in ten cancer deaths happen in low- and middle-income countries, where radiotherapy, pathology, surgery and drugs are scarce.